In vivo investigations using immunocompromised mouse models (NSG and/or NOD-SCID mice) carrying KRAS-mutant lung adenocarcinoma or TP53/RB1-mutant SCLC xenografts revealed that a single dose of CVB3 through intratumoral or systemic (via intraperitoneal injection) application leads to a marked tumor regression [24,28]. Here, KRAS is linked to small cell lung carcinoma.